



Assessing Antibiotic Resistance in *Helicobacter pylori*: Comparative Insights from Phenotypic and Genotypic Resistance Testing


Phornphan Sornchuer¹, Pornpen Gumnarai^{2,3}, Ratha-Korn Vilaichone^{3,4}

¹ Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani, 12120, Thailand
² Department of Biochemistry, Faculty of Medicine, Thammasat University, Pathum Thani, 12120, Thailand
³ Department of Medicine, Faculty of Medicine, Center of Excellence in Digestive Diseases and Gastroenterology Unit, Thammasat University, Pathum Thani, 12120, Thailand
⁴ Chulabhorn International College of Medicine (CICM), Thammasat University, Pathum Thani, 12120, Thailand

Introduction

Helicobacter pylori is a Gram-negative bacterium recognized as a major causative agent of peptic ulcer disease (Figure 1). Antibiotic resistance in *H. pylori* remains a major challenge in clinical management, particularly for clarithromycin (CLA) and levofloxacin (LVX). While phenotypic methods such as the E-test are widely used in routine practice, genotypic assays targeting resistance-associated mutations provide rapid and precise alternatives. This study aimed to compare phenotypic and genotypic resistance testing in *H. pylori* isolates.


Figure 1: *H. pylori* infection as a major cause of peptic ulcer disease.



Methodology

Twelve clinical isolates of *H. pylori* were subjected to antimicrobial susceptibility testing against CLA and LVX using the E-test. In parallel, genotypic resistance analysis was performed by Sanger sequencing (Figure 2). Sequencing targeted the *23S rRNA* gene, focusing on mutations A2142G and A2143G associated with CLA resistance, and the *gyrA* gene, focusing on amino acid substitutions at codons N87K and D91N/Y linked to LVX resistance (Figure 3). Results of phenotypic and genotypic testing were compared to assess concordance.

Figure 2. Schematic representation of the methodology employed in this study.



Results

For clarithromycin, concordance between E-test and genotypic testing was observed in 10 of 12 isolates. Two isolates exhibited phenotypic resistance without detectable *23S rRNA* mutations. For levofloxacin, concordance was also 10 of 12 isolates: one isolate harbored resistance-associated *gyrA* mutations despite phenotypic susceptibility, while another demonstrated phenotypic resistance in the absence of genotypic alterations. Overall, 20 of 24 comparisons (83.3%) were concordant across both antibiotics (Table 1).




Figure 3: Mutations in *23S rRNA* (left) and *gyrA* (right) genes associated with resistance to clarithromycin (CLA) and levofloxacin (LVX).

Table 1. Comparison of phenotypic and genotypic resistance profiles among *H. pylori* isolates.

Isolate #	Clarithromycin		Levofloxacin	
	E-test	Genetic testing	E-test	Genetic testing
1	S	S	S	S
2	R	R	S	R
3	R	R	R	R
4	R	R	R	R
5	R	S	R	S
6	R	R	R	R
7	R	R	R	R
8	R	R	S	S
9	R	S	S	S
10	R	R	R	R
11	R	R	R	R
12	R	R	S	S

Conclusion

This study demonstrated a high degree of concordance between phenotypic and genotypic methods for detecting clarithromycin and levofloxacin resistance in *H. pylori*. Genotypic testing offers the advantage of rapid, mutation-specific detection, independent of bacterial growth conditions, and can uncover resistance even when phenotypic results are ambiguous. The observed discordances underscore the limitations of relying solely on a single method. Incorporating genotypic assays into routine diagnostics holds the potential to enhance the precision of resistance detection, enabling more effective and individualized antimicrobial therapy for *H. pylori* infection.

References

• Contreras M, Mujica H, Garcia-Amado M. Molecular tools of antibiotic resistance for *Helicobacter pylori*: an overview in Latin America. *Frontiers in Gastroenterology*. 2024;3.
• Samanic I, Dadic B, Sanader Marsic Z, Dzelalija M, Maravic A, Kalinic H, et al. Molecular Characterization and Mutational Analysis of Clarithromycin- and Levofloxacin-Resistance Genes in *Helicobacter pylori* from Gastric Biopsies in Southern Croatia. *Int J Mol Sci*. 2023;24(19).